The endocannabinoid system as an emerging target of pharmacotherapy - Wikidata - wikimedia - TriplyDB

The endocannabinoid system as an emerging target of pharmacotherapy

The endocannabinoid system as an emerging target of pharmacotherapy

http://www.wikidata.org/entity/Q24648473

about

Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells Cannabinoids for fibromyalgia Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodents Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase Marijuana use and long-term mortality among survivors of acute myocardial infarction Is lipid signaling through cannabinoid 2 receptors part of a protective system?Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration Novel cannabinoid receptors Cannabinoids for fibromyalgia Cannabinoids for chronic neuropathic pain Endocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significance Cannabinoid receptor type-1: breaking the dogmas The involvement of TRPV1 in emesis and anti-emesis Anticancer mechanisms of cannabinoids Cannabis sativa: The Plant of the Thousand and One Molecules Emerging drugs of abuse: current perspectives on synthetic cannabinoids An Overview of Potential Targets for Treating Amyotrophic Lateral Sclerosis and Huntington's Disease Legal highs: staying on top of the flood of novel psychoactive substances Ontogenetic modifications of neuronal excitability during brain maturation: developmental changes of neurotransmitter receptors Chemical probes of endocannabinoid metabolism Is the cardiovascular system a therapeutic target for cannabidiol?Cannabinoids as therapeutic agents in cancer: current status and future implications Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization The role of endocannabinoids system in fatty liver disease and therapeutic potentials Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction Immune mechanisms in cerebral ischemic tolerance Metabolic syndrome: an important risk factor for Parkinson's disease Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?Differences in spontaneously avoiding or approaching mice reflect differences in CB1-mediated signaling of dorsal striatal transmission Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain Precision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive Astrocytes Endocannabinoid regulation of β-cell functions: implications for glycaemic control and diabetes Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome Phenazepam and cannabinomimetics sold as herbal highs in New Zealand

P2860

Q21144343-93E198C9-80B0-4F19-9DC6-355BD1F13ED0 Q24188267-909EAF2F-C2DA-4A22-8273-6E1928C547AD Q24595633-AA71F033-7B34-490F-B4B5-1508E077C620 Q24606148-78050AF8-470A-4E39-B041-E091D5D836B9 Q24613945-A35E9DAB-2B3E-4849-9E60-9F63EC0C1583 Q24620186-B57E5868-7D7A-4EF6-A6C2-6EC26C7C6E78 Q24629571-0E1B40BE-B2EA-4ADF-AFB5-5DBB5804A0B9 Q24633122-1EFFF5FD-5767-4E3E-BF66-09287D679EDE Q24643957-F56ECDC1-497C-498A-85B4-D6F43DEAE54A Q24648835-9F01EC26-C40F-47BC-B3A6-41F22A5C2011 Q24649936-20371D3C-E9B9-40C5-9822-046F780D4242 Q24651712-0925C160-42FB-4480-BE9A-9C683101B616 Q24681482-287ED717-CFE4-44E0-8626-D1D03C517BE9 Q26471052-7FC17783-CB61-4672-AFD1-37B37B7A94D8 Q26472068-EE07DA71-1B81-423C-AB02-C947B64F237F Q26739831-0A6F80A9-46EF-4093-8052-1E767305D229 Q26745261-A5D88700-877F-4B40-901C-B82FAF8A94C9 Q26745801-E8BBEC25-2E8B-4E9B-8D8A-01984417FBAD Q26750399-C7CDDDB1-C435-4A0D-BBA6-78D522E50E0F Q26766409-0A92542F-B316-46B1-B026-9610577BBC51 Q26778885-45A3FDE0-A037-40BD-BED5-FBC2E6757CB1 Q26796027-88609863-E26F-4DCD-8E74-01682A5730D2 Q26799231-875A94E7-3B4F-42BD-B1B2-3723225F2689 Q26823747-0C2151C7-727E-4C2A-9E20-93CAB6E75432 Q26863202-B171E668-C8B2-4963-AD4C-F3DA956956E0 Q26865370-79432A09-8B52-4470-B157-C8CCE7C7DDBE Q26866298-940123A2-164F-4A9F-8A6B-96B1DC6EA999 Q27001165-EB245492-5901-469A-AB3E-5A2A878C5643 Q27009287-A2114E3A-8858-44F7-A735-A47DD796024A Q27009466-A9F70F28-9CD5-4EA0-92FE-8845883BF95C Q27014154-298F6994-E566-4114-B823-4DBCAD0C3964 Q27022067-3337EFDF-4CCC-40B6-B1BB-8D30CE1EDF54 Q27023711-861A4FE3-2EA0-428C-A39F-0C3C8F966D31 Q27025612-F01CEB80-ACB0-4855-9BA9-653DA1A994FF Q27307029-B913C718-0F39-4AF1-8200-74D818EB21A9 Q27655121-0A15622F-DEFD-4050-9341-49179C91E711 Q28078621-48E37B1D-79F1-492D-884D-B7058A83D343 Q28078897-C8B25424-1F0A-464D-B93E-A1A7C681341D Q28244460-C4F8FEF2-0758-41B0-86A4-C4C12C5886DC Q28273694-2571D51F-B6E1-4D27-8B9B-FB18F276BF67

P2860

The endocannabinoid system as an emerging target of pharmacotherapy

http://www.wikidata.org/entity/Q24648473

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

The endocannabinoid system as an emerging target of pharmacotherapy

@ast

The endocannabinoid system as an emerging target of pharmacotherapy

@en

The endocannabinoid system as an emerging target of pharmacotherapy

@nl

type

label

The endocannabinoid system as an emerging target of pharmacotherapy

@ast

The endocannabinoid system as an emerging target of pharmacotherapy

@en

The endocannabinoid system as an emerging target of pharmacotherapy

@nl

prefLabel

The endocannabinoid system as an emerging target of pharmacotherapy

@ast

The endocannabinoid system as an emerging target of pharmacotherapy

@en

The endocannabinoid system as an emerging target of pharmacotherapy

@nl

P1433

Q24648473-57203277-E75E-4297-8384-800475B4BF0D

P1476

Q24648473-BB728312-F065-425E-8F54-05EF49ED0EB4

P2093

Q24648473-B829B349-04F0-4840-A038-DBBBA7729C14

Q24648473-CE0C2324-ACAD-4BCB-8F53-84B214785DAA

Q24648473-FAA3299D-232E-489D-833E-039915E048FE

P2860

Q24648473-0012DF63-ECD3-4DA4-B456-97A8F4D4D805

Q24648473-00413AEF-84A7-4904-8581-35A02769CA9A

Q24648473-004B45CB-6FC4-4197-A9C9-D9314A8DD6FA

Q24648473-00B7450B-5C37-426C-BC7C-71C935737CED

Q24648473-0135947C-92BB-4B7D-9C48-6E832895A3E2

Q24648473-01601755-BB19-4496-80E3-35107D2A2672

Q24648473-026D1DE3-CB25-4DAF-91EB-6DBAF8D22E4F

Q24648473-0283DA9D-FC71-4541-BD12-161E668B1298

Q24648473-028E139B-FCC4-42C3-84EC-EDF1188F9B4D

Q24648473-02E7B897-124A-46A6-81F5-760CFE217DD2

P304

Q24648473-F9A00A92-85C7-4640-9429-461B2907D6C2

P31

Q24648473-7E13E12B-F638-49F2-80FF-5A56A2C989B5

P3181

Q24648473-16B23BE5-CDAA-43FA-B0E9-F606536A21F2

P356

Q24648473-5E560CF1-5539-4EFE-92A4-0B4676D2F0DB

P407

Q24648473-BA9A4135-796B-4606-9F22-533EB82AFA8C

P433

Q24648473-A8633356-DDDF-451E-9C37-A7757DC9276A

P478

Q24648473-11D6CD49-1A2D-42DE-9FF9-DE9E0D7D685D

P577

Q24648473-0DE21741-5FD3-4FD0-9557-95CAB61C0FDC

P5875

Q24648473-59E8EC86-43BC-4DDF-91C5-9EB22F27AE23

P698

Q24648473-928F760D-6C49-4B6D-861D-936A704BE4B5

P921

Q24648473-5EBF5534-14AB-4D0B-B0A7-6E919B1C39D2

Q24648473-7BCE3E1E-B228-46C0-87CF-448BB37B11AF

P932

Q24648473-D9E720DB-B58C-43C2-858D-71D5FE496125

P3181

P356

P1433

Pharmacological Reviews

P1476

The endocannabinoid system as an emerging target of pharmacotherapy

@en

P2093

George Kunos

http://www.w3.org/2001/XMLSchema#string

Pál Pacher

http://www.w3.org/2001/XMLSchema#string

Sándor Bátkai

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain

Ethanol consumption and resistance are inversely related to neuropeptide Y levels

The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract

Anti-spasticity agents for multiple sclerosis

Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo

P304

389-462

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

457761

http://www.w3.org/2001/XMLSchema#string

P356

10.1124/PR.58.3.2

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6821989

http://www.w3.org/2001/XMLSchema#string

P698

16968947

http://www.w3.org/2001/XMLSchema#string

P921

endocannabinoid system

pharmacotherapy

P932

2241751

http://www.w3.org/2001/XMLSchema#string